JP2019521182A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521182A5
JP2019521182A5 JP2019517169A JP2019517169A JP2019521182A5 JP 2019521182 A5 JP2019521182 A5 JP 2019521182A5 JP 2019517169 A JP2019517169 A JP 2019517169A JP 2019517169 A JP2019517169 A JP 2019517169A JP 2019521182 A5 JP2019521182 A5 JP 2019521182A5
Authority
JP
Japan
Prior art keywords
enteric
dry weight
coated capsule
capsule according
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521182A (ja
JP7016353B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/064422 external-priority patent/WO2017216165A1/en
Publication of JP2019521182A publication Critical patent/JP2019521182A/ja
Publication of JP2019521182A5 publication Critical patent/JP2019521182A5/ja
Application granted granted Critical
Publication of JP7016353B2 publication Critical patent/JP7016353B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517169A 2016-06-13 2017-06-13 オキサレート関連障害を処置または防止するための組成物および方法 Expired - Fee Related JP7016353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650828-5 2016-06-13
SE1650828 2016-06-13
PCT/EP2017/064422 WO2017216165A1 (en) 2016-06-13 2017-06-13 Compositions and methods for the treatment or prevention of oxalate-related disorders

Publications (3)

Publication Number Publication Date
JP2019521182A JP2019521182A (ja) 2019-07-25
JP2019521182A5 true JP2019521182A5 (https=) 2020-07-27
JP7016353B2 JP7016353B2 (ja) 2022-02-04

Family

ID=59067657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517169A Expired - Fee Related JP7016353B2 (ja) 2016-06-13 2017-06-13 オキサレート関連障害を処置または防止するための組成物および方法

Country Status (12)

Country Link
US (2) US10765709B2 (https=)
EP (1) EP3468572B1 (https=)
JP (1) JP7016353B2 (https=)
CN (1) CN109641019A (https=)
AU (1) AU2017286220A1 (https=)
CA (1) CA3023042A1 (https=)
ES (1) ES2913398T3 (https=)
IL (1) IL263477A (https=)
JO (1) JOP20180110A1 (https=)
MA (1) MA45226A (https=)
TN (1) TN2018000420A1 (https=)
WO (1) WO2017216165A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468572B1 (en) * 2016-06-13 2022-03-02 OxThera Intellectual Property AB Compositions and methods for the treatment or prevention of oxalate-related disorders
US20210386793A1 (en) * 2018-10-04 2021-12-16 Oxthera Intellectual Property Ab New medical use of oxalate-reducing bacteria
CN110607262B (zh) * 2019-09-25 2022-03-25 君维安(武汉)生命科技有限公司 一种干预炎性肠炎的益生菌组合物及其筛选方法和应用
EP3839039A1 (en) * 2019-12-16 2021-06-23 4D Pharma Research Limited Providing bacterial biomass with improved storage stability
BR112022013867A2 (pt) * 2020-01-14 2022-09-13 Synlogic Operating Co Inc Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial
CA3175041A1 (en) * 2020-03-10 2021-09-16 Federation Bio Inc. Microbial consortia for the treatment of disease
EP4043018A1 (en) * 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
CA3216136A1 (en) * 2021-04-30 2022-11-03 Aaron Blake Cowley Compositions for preserving anaerobic microorganisms and methods of making and using the same
WO2023102091A2 (en) * 2021-12-01 2023-06-08 Federation Bio, Inc. Microbial consortia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
BG61712B1 (bg) * 1994-12-29 1998-04-30 "Ел Би Булгарикум" ЕАД закваски за българско кисело мляко и млечнокисели продукти и методи за получаването им
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
JP4996780B2 (ja) 1997-05-23 2012-08-08 オクセラ インコーポレイテッド シュウ酸塩関連疾患を予防するためのシュウ酸塩分解微生物またはシュウ酸塩分解酵素
WO2005097176A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Modulating oxalate transport
CA2608862C (en) 2004-06-11 2020-05-05 Trustees Of Tufts College Silk-based drug delivery system
WO2007070052A2 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
JP5558002B2 (ja) 2005-12-16 2014-07-23 オクセラ インコーポレイテッド シュウ酸塩低減化のための組成物および方法
JP5193626B2 (ja) 2008-02-20 2013-05-08 日本曹達株式会社 微生物農薬製剤の保存方法
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
EP3468572B1 (en) * 2016-06-13 2022-03-02 OxThera Intellectual Property AB Compositions and methods for the treatment or prevention of oxalate-related disorders

Similar Documents

Publication Publication Date Title
JP2019521182A5 (https=)
US10765709B2 (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
US10758561B2 (en) Composition based on xyloglucan and proteins for the treatment of intestinal disorders
JP3633936B2 (ja) センナ剤形
JP2020527580A5 (https=)
BR112019016705A2 (pt) composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
JP2017515888A (ja) 自己消化の治療用組成物
JP5850518B2 (ja) 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
Chan et al. Short bowel syndrome in adults—part 4-A. A guide to front line drugs used in the treatment of short bowel syndrome
US12569475B2 (en) Method for eradicating helicobacter pylori infection in patients regardless of body mass index
CN105073104A (zh) 卡巴他赛及其治疗转移性前列腺癌的用途
Manz et al. Treatment algorithm for moderate to severe ulcerative colitis.
RU2812928C2 (ru) Твердая композиция для доставки
US20210386793A1 (en) New medical use of oxalate-reducing bacteria
ZA200500064B (en) Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
Reckitt Benckiser The effectiveness of alginate therapy in managing gord
JP5626698B1 (ja) カルシウム低吸収型経口リン吸着剤
Özgüney Conventional and novel pharmaceutical dosage forms on prevention of gastric ulcers
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
KR20250151351A (ko) 변형-방출형 알기네이트-기반 조성물
CA3260258A1 (en) PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING LANTHAN AND ITS USE IN A METHOD OF TREATMENT OF HYPEROXALURIA
WO2009120054A1 (es) Metoclopramida de liberación prolongada de 24 horas
CN111617065A (zh) 普伐他汀钠在制备治疗新冠肺炎药物中的应用